从临床样本中生成肺腺癌类器官的方案。
Protocol for generation of lung adenocarcinoma organoids from clinical samples.
机构信息
Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China.
International Cancer Center, Shenzhen University School of Medicine, Shenzhen, Guangdong 518060, China.
出版信息
STAR Protoc. 2020 Dec 28;2(1):100239. doi: 10.1016/j.xpro.2020.100239. eCollection 2021 Mar 19.
Human cancer tissue-derived organoids maintain the mutational spectrum and histological characteristics of their parental tumors and thus provide a platform for predicting patients' responses to anticancer drugs. Here, we provide a fully detailed, step-by-step protocol to derive lung adenocarcinoma organoids from primary tumor tissues. Organoid lines can be generated with a success rate of 80% using our protocol. For complete details on the use and execution of this protocol, please refer to Li et al. (2020).
人源肿瘤组织衍生类器官保留了其亲本肿瘤的突变谱和组织学特征，因此为预测患者对抗癌药物的反应提供了一个平台。在此，我们提供了一个从原发性肿瘤组织中获得肺腺癌类器官的详细、全面的分步方案。使用我们的方案，类器官系的生成成功率可达 80%。有关该方案使用和执行的完整详细信息，请参考 Li 等人（2020 年）。
Zotero 插件